Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 5/20 | 0.38 |
| ▸ | HTR1B | P28222 | 4/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CFB | P00751 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215147 | 0.75 | ADRA2A (0.40) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL12437177 | 0.75 | HTR1D (0.50) | HTR1DADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL12437176 | 0.75 | HTR1D (0.50) | HTR1DADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL2214929 | 0.75 | HTR1D (0.50) | HTR1DADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL768916 | 0.75 | ADRA1A (0.53) | UGT2B17ADRA2AADRA1ACYP2D6 | |
| SCHEMBL4783949 | 0.73 | TAS1R3 (0.44) | ADRA2AADRA1A | |
| SCHEMBL1975897 | 0.73 | UGT2B17 (0.49) | UGT2B17KDM4C | |
| SCHEMBL12442744 | 0.72 | LMNA (0.60) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| SCHEMBL1718475 | 0.72 | LMNA (0.60) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Hydrochloric Acid SCHEMBL3501970 | 0.71 | LMNA (0.59) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426454-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20110178144-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-2188262-A1 | HETEROCYCLYL SUBSTITUTED FUSED CARBOCYLES USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS GLAUCOMA AND PAIN | Allergan, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009023758-A1 | HETEROCYCLYL SUBSTITUTED FUSED CARBOCYLES USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS GLAUCOMA AND PAIN | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-8815923-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815923-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815923-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130217739-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217739-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217739-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8426454-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426454-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110178144-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2188261-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2188262-A1 | HETEROCYCLYL SUBSTITUTED FUSED CARBOCYLES USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS GLAUCOMA AND PAIN | Allergan, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023758-A1 | HETEROCYCLYL SUBSTITUTED FUSED CARBOCYLES USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS GLAUCOMA AND PAIN | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023757-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023758-A1 | HETEROCYCLYL SUBSTITUTED FUSED CARBOCYLES USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS GLAUCOMA AND PAIN | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023757-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | UGT2B17 698/4885HTR1D 3687/4885HTR1B 2877/4885 |
| US-20130217739-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | UGT2B17 698/4885HTR1D 3687/4885HTR1B 2877/4885 |
| US-20110178144-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | UGT2B17 698/4885HTR1D 3687/4885HTR1B 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.